Spain’s competition watchdog has slapped a 39 million-euro ($38.45 million) fine on US-based Merck for anti-competitive behaviour in a case brought by Spanish rival Insud Pharma over a contraception device.
The CNMC antitrust agency said in a statement on Tuesday Merck’s local unit, which had a monopoly on vaginal contraceptive rings in Spain between 2002 and 2018 with its Nuvaring device, prevented Insud Pharma in 2017 from marketing its own device through deceptive practices.
Read more: Merck In $40B Deal For Cancer Biotech SeaGen
Merck Sharp & Dohme (MSD), the official name of Merck & Co outside the United States and Canada obtained a court order barring Insud Pharma from manufacturing the devices in Spain, where it has all its operations, hence preventing sales all over the world, the CNMC said.
“MSD deployed a strategy of deception with the court, hiding relevant factual and technical information,” it said, calling it a very serious infringement that constituted an abuse of dominant position.
Featured News
Pfizer Settles Remaining Effexor XR Antitrust Claims for $25.5 Million
Apr 29, 2024 by
CPI
South Korean Regulator Approves LG Uplus and Kakao Mobility EV Charging Venture
Apr 29, 2024 by
CPI
Federal Judge Dismisses Doctors’ Antitrust Suit Against Ohio Health System
Apr 29, 2024 by
CPI
Paramount CEO Bob Bakish Steps Down as Merger Inches Closer
Apr 29, 2024 by
CPI
EU Brands Apple’s iPadOS as Gatekeeper in Tech Crackdown
Apr 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI